Written by David Platt
Summary:
Many people don’t think much about their kidneys until something seems off. You may experience some swelling in the feet that stays around a bit longer than expected, or suffer from heavy fatigue that is so constant that it just becomes your new normal. Sometimes, even minor changes in urination can be a clue that a bigger issue might be brewing beneath the surface.
The kidneys are critical to bodily function. They handle key filtering duties day after day: they clear away waste, manage body fluids, regulate minerals, and they also help keep blood pressure under control. When kidney function slips, toxins, along with extra fluid, can slowly build up in the body, bit by bit.
Right now, chronic renal disease is showing up more often. Part of that is due to diabetes, high blood pressure, obesity, and the simple reality of aging populations. At the same time, researchers are paying closer attention to what might be the latest treatment for chronic kidney disease, plus how newer therapies may slow long-term kidney damage earlier on.
Some investigational research, including work being explored by Bioxytran, Inc., looks into kidney hypoxia, inflammation, scarring, and oxygen-related tissue harm that research suggests is connected to how chronic kidney disease (CKD) tends to progress.
CKD shows up when the kidneys slowly, over time, lose their ability to filter out waste from the blood.
When kidneys are healthy, they help keep fluid balance steady, clear out toxins, and manage electrolyte and potassium levels. CKD typically takes a while to show up, usually unfolding across several years. In the beginning, many patients do not initially notice symptoms. As the kidney injury gets worse, the body starts having trouble keeping up with normal fluid and waste balance, causing swelling (edema), and comorbidities affecting other organs..
Clinicians split CKD into five stages depending on eGFR readings. Early stages might mean relatively mild kidney damage, but later stages can move toward end-stage renal disease. At that point, dialysis is needed, or in extreme cases, a kidney transplant could become necessary.
Kidney disease is often called a “silent condition” because symptoms may appear gradually.
Since symptoms can be slow to advance, many patients only find out about CKD during routine blood or urine checks. Regular visits to primary care for checkups and screenings allow patients to take action early, the best route to help to slow progression, before serious damage shows up.
Several conditions can damage the kidneys over time.
High blood sugar damages small blood vessels inside the kidneys and reduces their filtering ability.
Long-term hypertension puts stress on the kidney blood vessels and tissues, gradually lowering kidney function.
Researchers are also looking at how kidney hypoxia might end up fueling inflammation, fibrosis, and this ongoing, progressive kidney injury.
Different causes can mean you need different kidney medications and kidney treatment approaches that depend on the exact trigger, not just the symptoms alone.
There is no complete cure for CKD yet, but most treatments for chronic kidney disease can help slow down disease progression and shield remaining kidney function by measurable markers.
One of the biggest questions patients could ask is what the latest treatments for chronic kidney disease are.
Newer treatment strategies are less about just coping with symptoms and more about targeting inflammation, fibrosis, and immune signaling, too, in a broader mechanism approach.
Some newer therapies include:
Researchers are also studying:
Scientists are hoping that these approaches may, at some point, help in building a new kidney drug or even a completely new medicine for kidney disease that aims straight at fibrosis and tissue damage in a more direct way.
Simultaneously, research is still moving forward on a new drug for polycystic kidney disease, with the goal to slow cyst growth and preserve as much kidney function as possible.
Emerging research on kidney hypoxia and fibrosis is something researchers are really leaning into lately, because inflammation and a kind of scarring process over time seem to quietly damage kidney tissue.
There is also a thought that proteins such as Galectin-3 might help drive fibrosis, collagen buildup, and stubborn long-term kidney scarring. So now scientists are looking at treatments that could stop or interrupt those inflammatory routes earlier, before the damage gets too far along.
Current research areas include:
Bioxytran, Inc. is one of the companies looking into investigational oxygen carrier tech and Galectin-3-centered approaches that are tied to kidney hypoxia research and fibrosis-related work.
Even though these therapies are still in the research stage, investigators think this kind of category could, in the end, help future kidney care strategies, and also support the development of a brand new kidney drug for fibrotic-related conditions.
Simple blood and urine tests can often detect kidney disease before symptoms become severe. Early diagnosis may help delay dialysis and preserve kidney function longer.
Living with CKD usually requires regular monitoring and long-term care, but many people continue working, traveling, and staying active while managing the condition.
Kidney research keeps moving past the classic blood pressure angle, moving toward therapies aimed at inflammation, scar-like fibrosis, oxygen loss, and immune messaging.
In labs, investigators are looking closely at how fibrosis and kidney hypoxia (tissue death) might together drive the long-term damage. It’s possible that oxygen-based treatments and Galectin-3 targeting strategies could someday help curb CKD progression.
Bioxytran, Inc. is still probing its investigational oxygen therapeutic, along with carbohydrate-based science, that connects inflammatory signaling with fibrosis-tied kidney disease advancement.
As understanding keeps sharpening, upcoming breakthroughs, maybe even a new drug for kidney disease, could be brought about using these tracts of research. With further study and discovery, Bioxytran technologies could bring more options for people living with chronic kidney disease.
Early signs can show up as fatigue, puffy areas in the feet or legs, foamy urine, and changes in urination, like going more often or fewer times.
More recent approaches usually aim at inflammation control, fibrosis reduction, dealing with oxygen-related tissue stress, and newer kidney medications, including GLP-1 receptor drugs, that have been studied for renal protection.
Right now, there is no full cure for CKD, but starting kidney care early can help slow down worsening and help preserve kidney function, for longer.
Clinicians often use ACE inhibitors, ARBs, SGLT2 inhibitors, and a range of other kidney medications, depending on the underlying problem and the stage of disease.
In end stage renal disease, the kidneys no longer manage to filter waste well enough, so dialysis may be needed, or sometimes a kidney transplant, as an alternative.
